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Abstract
A standardized molecular test for the detection of Chlamydophila pneumoniae DNA in cerebrospinal fluid (CSF) would assist
the further assessment of the association of C. pneumoniae with multiple sclerosis (MS). We developed and validated a
qualitative colorimetric microtiter plate-based PCR assay (PCR-EIA) and a real-time quantitative PCR assay (TaqMan) for
detection of C. pneumoniae DNA in CSF specimens from MS patients and controls. Compared to a touchdown nested-PCR
assay, the sensitivity, specificity, and concordance of the PCR-EIA assay were 88.5%, 93.2%, and 90.5%, respectively, on a
total of 137 CSF specimens. PCR-EIA presented a significantly higher sensitivity in MS patients (p=0.008) and a higher
specificity in other neurological diseases (p=0.018). Test reproducibility of the PCR-EIA assay was statistically related to the
volumes of extract DNA included in the test (p=0.033); a high volume, which was equivalent to 100 ml of CSF per reaction,
yielded a concordance of 96.8% between two medical technologists running the test at different times. The TaqMan
quantitative PCR assay detected 26 of 63 (41.3%) of positive CSF specimens that tested positive by both PCR-EIA and
nested-PCR qualitative assays. None of the CSF specimens that were negative by the two qualitative PCR methods were
detected by the TaqMan quantitative PCR. The PCR-EIA assay detected a minimum of 25 copies/ml C. pneumoniae DNA in
plasmid-spiked CSF, which was at least 10 times more sensitive than TaqMan. These data indicated that the PCR-EIA assay
possessed a sensitivity that was equal to the nested-PCR procedures for the detection of C. pneumoniae DNA in CSF. The
TaqMan system may not be sensitive enough for diagnostic purposes due to the low C. pneumoniae copies existing in the
majority of CSF specimens from MS patients.
Citation: Tang Y-W, Sriram S, Li H, Yao S-y, Meng S, et al. (2009) Qualitative and Quantitative Detection of Chlamydophila pneumoniae DNA in Cerebrospinal Fluid
from Multiple Sclerosis Patients and Controls. PLoS ONE 4(4): e5200. doi:10.1371/journal.pone.0005200
Editor: Dong-Yan Jin, University of Hong Kong, Hong Kong
Received December 15, 2008; Accepted January 27, 2009; Published April 9, 2009
Copyright:  2009 Tang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: yiwei.tang@vanderbilt.edu
Introduction
C. pneumoniae is an obligate intracellular pathogen that was first
described as a cause of respiratory tract infections in humans [1].
A number of studies have suggested that C. pneumoniae infections
may be associated with multiple sclerosis (MS) while other studies
have found no association; this association and these studies have
been recently reviewed [2,3]. It is clear from these reviews that a
standardized protocol for the molecular detection of C. pneumoniae
would assist investigators who wish to further assess the association
of this pathogen with MS.
The detection of C. pneumoniae in clinical specimens has been
widely performed using PCR-based nucleic acid amplification
techniques [4,5] since the culture of this pathogen requires a cell
culture and is complicated [4,6]. Such PCR-based assays have
improved the diagnosis of C. pneumoniae infections significantly.
However, comparisons of different PCR assays for C. pneumoniae
have demonstrated performance issues [7,8] such that standard-
ization of the PCR assay has been recommended [9]. Moreover,
the possibility of low C. pneumoniae copies in the CSF suggests the
need for extremely sensitive PCR detection methods [10]. Several
approaches for increasing the sensitivity of PCR assays in CSF,
including specimen concentration by high-speed centrifugation
and Southern blots [11,12], efficient DNA extraction [12], as well
as nested-PCR methods [4,13], have been described. However,
high-speed centrifuges needed for specimen concentration may be
unavailable in the routine clinical microbiology laboratory,
Southern blots are impractical in high volume clinical microbiol-
ogy laboratories, and nested-PCR procedures have a risk for
carryover contamination and have not been recommended for use
in routine diagnostic procedures.
In the present study, we reported the development and
evaluation of a qualitative colorimetric microtiter plate-based
PCR assay (PCR-EIA) and a real-time quantitative PCR assay
(TaqMan) for detection of C. pneumoniae DNA in CSF. We applied
these assays to the detection of C. pneumoniae in MS and other
neurologic diseases (OND) controls due to the controversy in this
field [2,3]. The PCR-EIA assay was as sensitive as a comparative
nested-PCR and more sensitive than the TaqMan quantitative
PCR assay and offers a method more suitable for clinical
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5200laboratories. The quantitative PCR results from the TaqMan
assay demonstrate that C. pneumoniae often is present in low copy
numbers in the CSF of MS patients; this assay thus would not be
suitable for diagnostic purposes.
Methods
Objectives
The objective of this study was to develop a standardized
molecular test for the detection of C. pneumoniae DNA in CSF that
was suitable for use in a clinical microbiology laboratory. We
developed a qualitative PCR-EIA and a quantitative TaqMan
PCR assay for detection of C. pneumoniae DNA in CSF specimens.
These two PCR assays were compared to the nested-PCR assay in
order to determine their sensitivity, specificity, and concordance.
Finally, we validated these two PCR assays by testing CSF
specimens from patients who were diagnosed with MS or with
OND.
Participants
CSF specimens were selected from patients from the Vanderbilt
University Medical Center who satisfied the Poser criteria for the
diagnosis of clinically definite MS. Age- and sex-matched patients
with OND in whom CSF was being obtained for diagnostic studies
were recruited as controls. CSF specimens were collected through
routine lumber puncture procedures, aliquoted into 0.5 ml
freezing vials within 1 hour of collection, and stored at 270uC
or below prior to testing. A pooled clinical CSF specimen, which
was herpesvirus and C. pneumoniae-negative, was used for a spiking
assay to determine assay analytical sensitivities [14].
Description of Procedures
DNA extraction. Nucleic acid was extracted from either
0.2 ml (high sample volume) or 0.1 ml (low sample volume) of
CSF by using IsoQuick (Orca Research, Inc., Bothell, Wash.)
according to the manufacturer’s instruction as previously
described [15]. The low volume extracted DNA samples were
resuspended in 50 ml (low DNA content); the high volume samples
were resuspended in 25 ml (high DNA content) of water to provide
a4 6difference in DNA content between the low and high volume
extracted samples. Human b-actin gene was amplified as a
‘‘house-keeping’’ gene for each sample DNA extract to validate
quality and normalize quantity [16].
Qualitative PCR. A PCR-EIA assay was performed to detect
C. pneumoniae DNA according to the procedure published
previously [14,15]. In brief, 50 ml of a PCR mixture contained
the following: 16buffer, 1.5 mM MgCl2, 10% glycerol, 200 mM
dATP, dCTP, and dGTP, 100 mM dTTP, 90 mM dUTP, 10 mM
digoxigenin-11-dUTP (Roche Biochemicals, Indianapolis, IN),
1 mM each primer, 0.01 units/ml uracil N-glycosylase (UNG,
Epicentre Technologies, Madison, WI), 0.025 units/ml AmpliTaq
gold DNA polymerase (Applied Biosystems), and either 25 ml (high
volume) or 5 ml (low volume) of specimen DNA extract. The
reaction mixtures were placed in an ABI 9700 thermal cycler
(Applied Biosystems) programmed for a three-step PCR procedure
followed by an initial UNG activation as described previously
[14,15]. The primer set (Cpm1, 59-TTA CTT AAA GAA ACG
TTT GGT AGT TCA TTT-39 and Cpm2, 59-TAA ACA TTT
GGG ATC GCT TTG AT-39) was designed to amplify a 154-bp
portion of the C. pneumoniae major outer membrane protein
(MOMP) gene [17,18]. The amplification cycling conditions were
a 5 min degradation of the preamplified templates at 50uC and
then 50 cycles of denaturation at 94uC for 30 s, annealing at 55uC
for 30 s, and extension at 72uC for 45 s [14]. Amplification
products were then identified by detecting digoxigenin-labeled
PCR products with a PCR ELISA kit (Roche Biochemicals) as
previously described [14,15,19]. A C. pneumoniae-specific 59-
biotinylated capture probe (Cpmp, 59-ACT CCG AAT AAA
CCA ACG AGA TTG AAC GC-39) was applied to detect and
confirm the amplification product. Output signal was measured at
an optical density of 450 (OD450). A positive result was defined as
an OD450–OD490 value greater than or equal to 0.1.
Quantitative PCR. A real-time quantitative PCR assay was
performed on the 7700 ABI Prism Sequence Detector (Applied
Biosystems Foster City, CA). Sequences of primers and probe are
the same as the ones used for qualitative detection. The
amplicon was generated by PCR and was subsequently cloned
into the pCR2.1 vector (Invitrogen, Carlsbad, CA). Quantitative
pre- and post-DNA extraction standard curves were achieved by
using five 10-fold serial dilutions of a plasmid standard (pCR-
MOMP) containing the primer-spanning region of the C.
pneumoniae MOMP B gene [17,18]; this curve was determined
both pre- and post-DNA extraction. The plasmid standard DNA
concentration was calibrated by spectrophotometry at 260 nm.
The fluorophore probe was designed with a reporter dye, 6-
carboxyfluorescein (FAM) and a quencher dye, 6-
carboxytetramethylrhodomine (TAMRA), covalently linked to
the 59 and 39 ends, respectively [20,21]. An aliquot of either
25 ml (high DNA content) or 5 ml (low DNA content) of the
extracted nucleic acid was added to TaqMan Universal PCR
Master Mix (Applied Biosystems) containing 0.8 mMo fe a c h
primer and 0.4 mM probe to reach a final volume of 50 ml. The
TaqMan cycling conditions were a 2 min degradation of the
preamplified templates at 50uC and then 40 cycles of
denaturation at 95uC for 15 s and annealing and extension at
58uCf o r6 0s .
Nested-PCR. DNA amplification of the C. pneumoniae MOMP
gene was done using a touchdown nested-PCR technique as
described previously [22,23]. Briefly, DNA was extracted from
300 ml of CSF using the phenol chloroform method and dissolved
in 30 ml of Tris-EDTA buffer. The presence of C. pneumoniae was
examined by PCR using two different sets of internal and external
primers that are specific for the C. pneumoniae MOMP gene
[17,18]. Amplification of the outside product was done first using
the ‘‘touchdown’’ technique and 2 ml of the first product was then
subjected to a second amplification using internal primers. The
PCR products were visualized by 1.5% agarose gel electrophoresis
staining with ethidium bromide [22,23].
Ethics
This study protocol was approved by the Vanderbilt
University Institutional Review Board. Individual participants
in this study were required to give written informed consent. In
addition, the research involved the study of existing diagnostic
specimens in which the information was recorded by the
Investigator in such a manner that subjects could not be
identified, directly or through identifiers linked to the subjects.
Moreover, these diagnostic specimens had been collected before
the research project began.
Statistical methods
Data were entered into Microsoft Excel for further analysis.
Results obtained from the nested-PCR were used as the evaluation
standard. Comparisons of sensitivity, specificity and concordance
by x
2 test were performed with Epi Info
TM software (version 6;
Centers for Diseases Control and Prevention, Atlanta, Ga.). A p
value of #0.05 was considered statistically significant.
Detecting C. pneumoniae in CSF
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A total of 137 CSF specimens were included in the study to
validate the PCR-EIA assay by using the nested-PCR procedure as
the reference. The sensitivity and specificity of the PCR-EIA assay
were 88.5% and 93.2% respectively when a high sample volume
(equivalent to 100 ml CSF per reaction) of the CSF specimen was
used (Table 1). The agreement rate between the PCR-EIA and the
nested-PCR assays was 90.5%. The sensitivity of the PCR-EIA
assay was significantly higher in specimens collected from MS
patients (92.8%) than those from OND (55.6%) (p=0.008). In
contrast, the specificity was significantly higher in specimens
collected from OND patients (97.9%) than those from MS (72.7%)
(p=0.018).
Test reproducibility of the PCR-EIA assay was determined on
31 CSF specimens by two different laboratorians on both high
DNA content specimens (100 ml CSF per reaction) and low DNA
content specimens (20 ml CSF per reaction). With the high DNA
content specimens, a test reproducibility of 96.8% was reached
between two different laboratorians (Table 2), which was
significantly higher than that in low volume (74.2%) (x
2
M-
H=4.53, p=0.033). The reproducibility appears to be a function
of copy number of organisms per unit volume of CSF and was not
confounded by other variables (p.0.05).
Quantitative standard curves were achieved by using five 10-
fold dilutions of a plasmid standard containing the primer-
spanning region of the C. pneumoniae MOMP gene covering
plasmid copies from 2.5 to 25,000 per reaction, which corre-
sponded to 25 to 250,000 copies/ml of CSF. A total of 79 CSF
specimens were tested to validate the quantitative TaqMan assay.
The TaqMan assay detected 26 specimens with a geometric C.
pneumoniae mean load equivalent to 774.1 (115.2–6419.8) copies/
ml of CSF (Table 3). All 26 positive specimens were from MS
patients with positive results by both PCR-EIA and nested-PCR
qualitative assays. TaqMan detected 12 (32.4%) of 37 CSF
specimens from relapsing remitting MS patients in contrast to 14
(41.2%) of 34 specimens from progressive MS (p.0.05). C.
pneumoniae loads measured by TaqMan were higher in CSF from
progressive MS (geometric mean load6standard deviation:
1,009.663.6 copies/ml) than in CSF from relapsing remitting
MS (567.763.6 copies/ml), but the difference was not statistically
significant (Figure 1). None of the OND controls that were positive
or negative by qualitative PCR were positive by TaqMan.
The post-DNA extraction test sensitivities of the PCR-EIA and
TaqMan assays were determined by detecting six 10-fold dilutions
of a plasmid standard covering plasmid copies from 0.025 to 2,500
per reaction. They were diluted using pooled C. pneumoniae-
negative CSF specimens and processed as clinical specimens in
triplicate, which corresponded to 0.25 to 25,000 copies/ml of
CSF. All 6 reactions from 2 experiments were tested positive by
the PCR-EIA assay for the dilution of 2.5 copies per reaction,
indicating a test sensitivity of 25 copies/ml of CSF, which was at
least 10 times more sensitive than the quantitative TaqMan assay
(Table 4).
Discussion
There is considerable controversy concerning the evidence for
the presence of C. pneumoniae in CSF either from MS patients or
from patients with other neurological diseases. The initial report of
the association of C. pneumoniae and MS included both isolation of
this microorganism by blinded cell cultures as well as the presence
of C. pneumoniae DNA in CSF by PCR [11,24]. A number of other
investigators subsequently have confirmed the presence of C.
pneumoniae DNA in CSF from MS patients by PCR methods,
although usually in a smaller percent of patients [12,25–30]. For
example, Lay-Schmitt initially was able to show the presence of C.
pneumoniae DNA in 22% of MS patients; this number increased to
over 50% when phenol/chloroform extraction techniques were
used [25]. A report by Geiffers found a high number of patients
with other neurological diseases that demonstrated the presence of
C. pneumoniae DNA in the CSF by PCR (21% for MS patients
versus 43% for OND controls) [27]. This OND group included a
number of individuals with inflammatory diseases including optic











PCR-EIA + PCR-EIA 2 PCR-EIA + PCR-EIA 2
Multiple sclerosis (MS) 80 64 5 3 8 92.8 72.7 90.0
Other neurologic diseases (OND) 57 5414 7 5 5 . 6 9 7 . 9 9 1 . 2
Total 137 69 9 4 55 88.5 93.2 90.5
doi:10.1371/journal.pone.0005200.t001
Table 2. Test reproducibility of PCR-EIA is related to extract volumes included in the PCR reaction mixture.
Clinical diagnosis Number tested
Number positive
by PCR-EIA High sample volume Low sample volume
Number matched Concordance (%) Number matched Concordance (%)
Multiple sclerosis (MS) 24 21 23 95.8 18 75.0
Other neurologic diseases (OND) 7 1 7 100.0 5 71.4
Total 31 22 30 96.8 23 74.2
doi:10.1371/journal.pone.0005200.t002
Detecting C. pneumoniae in CSF
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symptoms of MS. In addition, several of these investigators have
noted gene transcription of messenger RNA by C. pneumoniae in
CSF from MS patients suggesting active infection by this pathogen
[31,32].
In contrast, other investigators have been unable to either
isolate C. pneumoniae by cell culture [33,34] or detect any
chlamydial DNA in CSF from MS patients or controls [33–40]
although one investigator was able to grow C. pneumoniae from one
patient with MS despite negative PCR results in this patient [40].
In a collaborative study involving four different laboratories, the
presence of C. pneumoniae was examined in 52 blinded CSF samples
[41]. Dr. Sriram’s laboratory at Vanderbilt was able to detect C.
pneumoniae in 73% (22/30) of MS patients as compared to 22% (5/
22) of controls. Three other laboratories (Drs. C. Gaydos, Johns
Hopkins University, Baltimore MD; J. Boman, University
Hospital, Umea Sweden; and L. Tondilla, CDC, Atlanta, GA)
failed to show the presence of C. pneumoniae DNA in any of these
CSF samples.
These inconsistencies of results from different laboratories
strongly suggest that methodological problems are responsible.
This is not surprising, as there are no well-accepted methods and
techniques for demonstrating the presence of C. pneumoniae in CSF
[9,10]. Because of the difficulties in isolating C. pneumoniae in cell
cultures, nucleic acid amplification methods such as PCR-based
assays have become the method of choice for detection of this
microorganism [5,9]. However, PCR procedures often lack
sensitivity, reproducibility, and specificity when applied to direct
testing of clinical specimens [7,8,42]. This unsatisfactory perfor-
mance of PCR appears to be related to the presence of inhibitors
of the polymerase enzyme that are present in the clinical
specimens, degradation of DNA, and contamination by DNA
amplicons from previous testing. Other important issues related to
PCR testing include the collection/storage of specimens, extrac-
tion of nucleic acids, target region and choice of primers, PCR
method and reaction conditions, detection of amplification
products, and the prevention and identification of false-positive
and false-negative results.
The lack of standardized diagnostic methods for C. pneumoniae
infection has resulted in controversy concerning the role of this
microorganism in both atherosclerosis [43] and MS [2,3]. In
particular, PCR-based assays have been problematic. In a
multicenter comparison of PCR-based assays for the detection of
C. pneumoniae in endarterectomy specimens, the positivity rates
varied between 0 and 60% among laboratories using different
methods [44]. Similar technical problems may play an important
role in the discrepant PCR results from CSF from MS patients
tested in different laboratories. Ikejima and colleagues have
demonstrated that PCR conditions must be optimized in order
to obtain a signal for C. pneumoniae in the presence of low copy
numbers of the organism [12]. For example, DNA extraction by
the Qiagen QIAmp DNA Mini Kit with bacterial DNA extraction
rather than the Qiagen QIAmp Blood Mini Kit has been shown to
result in increased PCR sensitivity (20 copies versus 200 copies,
respectively). The same investigators also showed that the primers
for C. pneumoniae MOMP DNA gene had a 10-fold increase in
sensitivity in comparison with primers for the 16s RNA gene.
Smieja and colleagues have noted that replicate testing and the
performance of probit analysis may be necessary to overcome the
problems of dilution and statistical variability in the presence of
low copy numbers [45]. Both Boman and Yamamoto have
extensively reviewed many of the problems related to PCR assays
[5,10].
Microtiter plate-based PCR-enzyme linked amplification and
hybridization assays for the detection of C. pneumoniae as well as
other microorganisms have been described and are sensitive and
robust methods suitable for the clinical laboratory [15,46,47]. The
PCR-EIA assay as described in this report is simple, user-friendly,
and results can be obtained in the same day. An additional
antigen-antibody reaction was included as a signal amplification
step to enhance test sensitivity. A recent blinded proficiency study
indicated the PCR-EIA system detects as few as 1 copy/reaction
human herpesvirus-6 in spiked plasma specimens [47]. The test
sensitivity of the PCR-EIA in mock CSF samples is 25 C.
pneumoniae organisms per ml of CSF. This is comparable to the
sensitivity in mock CSF samples of the PCR assay described by
Ikejima et al [12], which had a sensitivity of 100 organisms per ml
of CSF. The nested-PCR assay used in this study has been shown
previously to be as sensitive as the PCR assay described by Ikejima
[12]. A uracil-N-glycosylase-based inactivation system was adapted
to control for possible amplicon carryover contamination
[14,15,19].
Several investigators have reported real-time PCR-based
fluorescence assays for detection of C. pneumoniae [48,49]. The
TaqMan system described in this report incorporated a real-time
format in which amplification and detection are accomplished
simultaneously. This method measured the accumulation of PCR
products using a fluorogenic probe and real-time laser scanning in
Figure 1. Dotplot of copy numbers of C. pneumoniae DNA in
relapsing remitting MS (left) and progressive MS (right)
patients. Horizontal bars indicated the geometric mean copy numbers,
which were 567.7 and 1,009.6 copies/ml (geometric mean load) for
relapsing remitting and progressive MS, respectively (p.0.05).
doi:10.1371/journal.pone.0005200.g001
Table 3. C. pneumoniae loads in CSF specimens determined












Negative 8 0 0
Discrepancy
c 80 0
Total 79 26 32.9
aBased on results obtained between PCR-EIA and nested-PCR assays.
bThese 26 quantifiable specimens were all from MS patients with a geometric
mean C. pneumoniae load equivalent to 774.1 (115.2–6419.8) copies/ml CSF.
cIncluded 5 nested-PCR+/PCR-EIA2 and 3 nested-PCR2/PCR-EIA+ CSF
specimens.
doi:10.1371/journal.pone.0005200.t003
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using a ‘‘closed’’ system [20,21]. In this study, real-time
quantitative PCR was not as sensitive as the PCR-EIA assay
and therefore is not recommended for initial diagnostic purposes
in CSF specimens. It could be useful, however, as a determinant of
C. pneumoniae load and response to therapy in those cases with
relatively high CSF content.
The sensitivity of the PCR-EIA assay was significantly higher in
specimens collected from MS patients (92.8%) than those from
OND (55.6%) (p=0.008). In contrast, the specificity was
significantly higher in specimens collected from OND patients
(97.9%) than those from MS (72.7%) (p=0.018). We believe that
this difference may be due to the fact that although C. pneumoniae
may be present in the CSF in a variety of neurological diseases and
not restricted to multiple sclerosis [27], this pathogen is more likely
to be found in the CSF from multiple sclerosis because the
proinflammatory mediators produced by chronic intracellular
chlamydial infections of ependymal cells located in the circumven-
tricular organ [50] may produce a toxic effect on nearby mature
CNS oligodendrocytes [51] and thus lead to demyelination and a
diagnosis of multiple sclerosis.
This study did not detect significant differences in CSF C.
pneumoniae loads between patients in different phases of MS.
Although the C. pneumoniae loads were higher in CSF from
progressive MS than that in relapsing remitting MS, the
difference in geometric mean copy numbers was not statistically
different.
This study has several key limitations. The first one is that the
presence of DNA in the CSF does not mean that infection is
playing a role in MS. This argues for the use of PCR-EIA to detect
heat shock protein 60 (Hsp-60) mRNA from the CSF of patients
with MS as was done by both Dong-Si et al [31] and Contini et al
[32]. Hsp-60 is produced by C. pneumoniae during its cryptic phase.
This study is being planned. A second one is that MS may not
have a single infectious cause [2] or may involve an infectious
trigger followed by an autoimmune response [3]. A sensitive PCR
assay for Hsp-60 mRNA would also, in part, address this
limitation. The final key limitation is that a nested-PCR assay
was used as the validation reference since there is no ‘‘gold
standard’’ technique available yet in the field. It is important to
recognize the limitations of any diagnostic techniques used in the
clinical laboratory.
In summary, the results of a quantitative PCR assay
demonstrate that some CSF samples from MS patients have a
low number of C. pneumoniae present. This confirms the argument
that an extremely sensitive PCR assay is needed [10]. Nested-PCR
methods have been used successfully, but nested procedures are
not ideal for use in a clinical laboratory. The PCR-EIA assay
described in this study is, however, more suited for a clinical
laboratory and should allow accurate and sensitive detection of C.
pneumoniae DNA in CSF.
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